BUILDING A LEADING ONCOLOGY FRANCHISE

DIFFERENTIATED CANDIDATES ADDRESSING CLEAR NEEDS

STRONG FINANCIALS, OPTIMALLY BUILDING VALUE

View our 2018 annual report.

Latest News

MEI Pharma to Present at the 29th Annual Oppenheimer Healthcare Conference
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advance
MEI Pharma Reports Second Quarter Fiscal Year 2019 Results and Operational Highlights
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting